Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Glaxo believes its plan for HIV treatment is a ‘game changer’
First Opinion By Dana P. Goldman To prevent another EpiPen controversy, the government should step in
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Mylan CEO claims ‘no one’s more frustrated than me’
Business By Damian Garde 5 questions about EpiPen pricing that Mylan CEO Heather Bresch has yet to answer
Business By Rebecca Robbins Sarah Jessica Parker cuts ties with Mylan in anger over EpiPen price hikes
Exclusive By Ike Swetlitz and Ed Silverman Mylan may have violated antitrust law in its EpiPen sales to schools, legal experts say
Business By Damian Garde The EpiPen was her ‘baby.’ Now this pharma CEO is in the hot seat over price hikes
As Seen on TV By Bob Tedeschi EpiPen goes for the gold: Drug maker, under fire for price hikes, blitzed Olympics with ads
Business By Ike Swetlitz High price of EpiPens spurs consumers, EMTs to resort to syringes for allergic reactions